Canaccord Genuity Remains Constructive on Itron (ITRI)

Canaccord Genuity maintained a Buy rating on Itron (NASDAQ: ITRI) but lowered its price target to $46.00 (from $55.00).

"While the diminished outlook tempers our bullishness on the company near term, we still find longer-term value in shares," said analyst John Quealy.

He thinks headwinds will remain in 2013. However, with "solid cash flow and the imminent CEO succession", he remains constructive.

He cut 2012 revenue and EPS estimates to $2.12 billion/$3.60 from $2.16 billion/$3.80.

For an analyst ratings summary and ratings history on Itron click here. For more ratings news on Itron click here.

Shares of Itron closed at $39.57 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• Regenxbio Inc. (RGNX) PT Raised to $32 at Baird
• Progyny (PGNY) PT Raised to $33 at Truist Securities